A Study of LY2940680 in Pediatric Medulloblastoma or Rhabdomyosarcoma
Status:
Withdrawn
Trial end date:
2016-07-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to find a recommended dose level of LY2940680 that can be safely
given to children with medulloblastoma or rhabdomyosarcoma that has returned or doesn't
respond to initial treatment. The study will also explore the changes in a cancer marker
levels. Finally, the study will help document any antitumor activity.